Benmelstobart

50 patients from 5 centers received protocol-specified therapy; 38% discontinued early. Median PFS was 14.9 months, and 1-year OS rate was 74.8%. 72% achieved objective response, with 83.3% of responders maintaining response >6 months. 92% experienced any grade AEs, and 78% had grade ≥3 events. 48% had immune-related AEs, with 6% experiencing grade ≥3 irAEs.

Benmelstobart plus anlotinib demonstrated promising efficacy and low toxicity in Chinese EGFR-positive advanced NSCLC patients who progressed after EGFR TKI therapy, suggesting a potential chemotherapy-free immunotherapy option. The combination showed a mPFS of 9 months and a mOS of 28.9 months, with a DCR of 87.3% and a mDoR of 19.8 months, outperforming previous studies. The therapy's favorable safety profile and oral administration convenience highlight its potential in the evolving treatment landscape for this patient population.

Benmelstobart plus anlotinib showed improved clinical outcomes for advanced RCC compared to sunitinib in the ETER100 trial, with a median PFS of 18.96 months vs 9.76 months, and ORR of 71.6% vs 25.1%. The combination reduced the risk of progression or death by 47%.

Benmelstobart plus anlotinib showed superior PFS (18.96 months vs 9.76 months) and ORR (71.6% vs 25.1%) compared to sunitinib in advanced RCC patients, with a safety profile consistent with each agent.